Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 370 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Double-dummy placebo Clear all
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Assessment of LBR-101 In Chronic Migraine

NCT02021773
View directory record Official record
Conditions
Chronic Migraine
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

NCT06215820
View directory record Official record
Conditions
Acute Pain, Post Operative Pain, Pain
Interventions
MR-107A-02, Tramadol, Placebo, Bunionectomy
Drug · Procedure
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

NCT00603382
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 11, 2026, 4:19 AM EDT
Withdrawn Phase 3 Interventional

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

NCT01674413
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Adalimumab PRN, Placebo
Drug
Lead sponsor
Peter Higgins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT04345367
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib 200 mg, Dupilumab 300 mg
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 11, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

NCT01900795
View directory record Official record
Conditions
Postsurgical Pain Due to Third Molar Extraction
Interventions
V117957, Ibuprofen, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 45 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Medication-based Analgesia in Humans- STUDY 2

NCT04036968
View directory record Official record
Conditions
Pain, Cannabis, Opioid Use
Interventions
Within-subject test of blinded study medications
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

NCT00453999
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 11, 2026, 4:19 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

NCT03509285
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alprazolam Placebo, Cenobamate placebo, Alprazolam, Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 11, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

NCT01667679
View directory record Official record
Conditions
Migraine, Headaches
Interventions
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 11, 2026, 4:19 AM EDT
Terminated Phase 4 Interventional Results available

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

NCT00484718
View directory record Official record
Conditions
Osteoarthritis
Interventions
celecoxib, Oxycodone, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 2 Interventional

Schizophrenia Study In Adults

NCT00049946
View directory record Official record
Conditions
Schizophrenia
Interventions
talnetant, risperidone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
31
States / cities
Scottsdale, Arizona • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional

A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine

NCT00300924
View directory record Official record
Conditions
Migraine
Interventions
Rizatriptan co-administered with Acetaminophen
Drug
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Kalamazoo, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00685841
View directory record Official record
Conditions
COPD
Interventions
Arformoterol tartrate inhalation solution, Salmeterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

NCT00492635
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction, Physiological
Interventions
Levitra (Vardenafil, BAY38-9456), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 11, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02171429
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Orlando, Florida • Topeka, Kansas • Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 11, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

NCT00143091
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
CP-316,311, Placebo, Sertraline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Bellevue, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 11, 2026, 4:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190
View directory record Official record
Conditions
Multifocal Motor Neuropathy (MMN), MMN
Interventions
Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Pomona, California • Rancho Mirage, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 11, 2026, 4:19 AM EDT